Photocure ASA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Photocure ASA with three other
pharmaceutical manufacturers in Europe:
Santhera Pharmaceuticals Holding AG
sales of 19.03 million Swiss Francs [US$19.91 million]
of which 100%
was Pharmaceutical Products),
Replek AD Skopje
(829.32 million Denar [US$15.51 million]
Science In Sport Plc
based in the United Kingdom
(£12.24 million [US$15.94 million]
During the year ended December of 2016, sales at
Photocure ASA were NOK 143.63 million (US$17.84 million).
increase of 6.6%
versus 2015, when the company's sales were NOK 134.72 million.
This was the third consecutive year of growth at Photocure ASA.
Sales of Hexvix Partner Sales saw an increase
that was more than double the company's growth rate: sales were up
13.6% in 2016, from
NOK 54.10 million to NOK 61.46 million.
Photocure ASA also saw significant increases in sales in
Hexvix/cysview Own Sales (up 12.7% to NOK 69.50 million)
Not all segments of Photocure ASA experienced an increase in sales in 2016:
sales of Other Sales fell 20.2% to NOK 5.22 million.
(However, this segment's sales were only a very small portion of the company's overall sales).